

Enrique M Ocio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5155219/publications.pdf>

Version: 2024-02-01

131
papers

8,379
citations

44069

48
h-index

48315

88
g-index

134
all docs

134
docs citations

134
times ranked

9039
citing authors

#	ARTICLE	IF	CITATIONS
1	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
2	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 2096-2107.	13.7	435
3	International prognostic scoring system for Waldenström's macroglobulinemia. <i>Blood</i> , 2009, 113, 4163-4170.	1.4	366
4	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017, 31, 2443-2448.	7.2	259
5	MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. <i>Leukemia</i> , 2013, 27, 1722-1728.	7.2	238
6	The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance. <i>Cancer Research</i> , 2006, 66, 5781-5789.	0.9	233
7	Response assessment in Waldenström's macroglobulinaemia: update from the International Workshop. <i>British Journal of Haematology</i> , 2013, 160, 171-176.	2.5	226
8	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). <i>Leukemia</i> , 2014, 28, 525-542.	7.2	214
9	Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 120-126.	1.6	207
10	Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. <i>Leukemia</i> , 2007, 21, 541-549.	7.2	187
11	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , the, 2019, 6, e459-e469.	4.6	174
12	PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. <i>Leukemia</i> , 2015, 29, 2110-2113.	7.2	170
13	5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1718-1727.	4.1	154
14	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. <i>Blood</i> , 2007, 110, 3744-3752.	1.4	144
15	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , 2010, 95, 794-803.	3.5	144
16	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	1.4	144
17	JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. <i>Blood</i> , 2007, 110, 709-718.	1.4	139
18	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136

#	ARTICLE	IF	CITATIONS
19	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. <i>Haematologica</i> , 2013, 98, 79-86.	3.5	132
20	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. <i>Blood</i> , 2013, 122, 3591-3598.	1.4	131
21	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016, 127, 3165-3174.	1.4	129
22	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. <i>Blood</i> , 2011, 118, 3419-3425.	1.4	123
23	New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. <i>Lancet Oncology</i> , 2008, 9, 1157-1165.	10.7	116
24	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. <i>Leukemia</i> , 2013, 27, 430-440.	7.2	112
25	6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. <i>British Journal of Haematology</i> , 2007, 136, 80-86.	2.5	109
26	Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 380-383.	1.4	107
27	Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity <i>In vitro</i> and <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 5216-5225.	0.9	98
28	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. <i>Blood</i> , 2016, 127, 1896-1906.	1.4	81
29	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	7.2	81
30	The cellular origin and malignant transformation of Waldenström macroglobulinemia. <i>Blood</i> , 2015, 125, 2370-2380.	1.4	80
31	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. <i>Blood</i> , 2009, 113, 3781-3791.	1.4	78
32	A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. <i>Leukemia</i> , 2013, 27, 2056-2061.	7.2	78
33	Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification. <i>Leukemia</i> , 2014, 28, 166-173.	7.2	76
34	Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. <i>Haematologica</i> , 2013, 98, 640-648.	3.5	75
35	Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease. <i>Clinical Cancer Research</i> , 2014, 20, 1542-1554.	7.0	75
36	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. <i>Leukemia</i> , 2015, 29, 705-714.	7.2	72

#	ARTICLE	IF	CITATIONS
37	Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. <i>Leukemia</i> , 2015, 29, 1186-1194.	7.2	71
38	Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. <i>Blood</i> , 2014, 124, 1300-1303.	1.4	67
39	Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. <i>American Journal of Hematology</i> , 2005, 78, 302-305.	4.1	66
40	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. <i>PLoS ONE</i> , 2012, 7, e34914.	2.5	61
41	The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. <i>Blood</i> , 2011, 117, 3613-3616.	1.4	59
42	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. <i>Leukemia</i> , 2009, 23, 2265-2274.	7.2	58
43	Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. <i>British Journal of Haematology</i> , 2019, 186, e117-e121.	2.5	58
44	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. <i>Haematologica</i> , 2008, 93, 57-66.	3.5	56
45	p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. <i>British Journal of Haematology</i> , 2008, 141, 598-606.	2.5	53
46	BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. <i>British Journal of Haematology</i> , 2007, 136, 414-423.	2.5	49
47	The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2019, 33, 2924-2933.	7.2	49
48	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.	5.7	48
49	Immunophenotypic and Cytogenetic Comparison of Waldenström's Macroglobulinemia with Splenic Marginal Zone Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 241-245.	2.1	47
50	Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. <i>Clinical Cancer Research</i> , 2013, 19, 2677-2687.	7.0	45
51	Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. <i>Leukemia</i> , 2005, 19, 1088-1091.	7.2	43
52	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	7.2	43
53	Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. <i>Oncotarget</i> , 2014, 5, 8284-8305.	1.8	43
54	The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care. <i>Clinical Cancer Research</i> , 2017, 23, 225-238.	7.0	42

#	ARTICLE	IF	CITATIONS
55	The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, e53-e55.	3.5	41
56	Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study. <i>Bone Marrow Transplantation</i> , 2004, 34, 729-738.	2.4	40
57	Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. <i>Blood</i> , 2014, 124, 3029-3031.	1.4	40
58	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	1.8	39
59	Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. <i>Haematologica</i> , 2020, 105, e116-e120.	3.5	38
60	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2020, 34, 3298-3309.	7.2	37
61	The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. <i>British Journal of Haematology</i> , 2008, 141, 470-482.	2.5	35
62	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3120.	2.4	35
63	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. <i>Haematologica</i> , 2012, 97, 1110-1114.	3.5	34
64	Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. <i>Haematologica</i> , 2017, 102, 922-931.	3.5	34
65	Future agents and treatment directions in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 127-141.	2.2	30
66	Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β -catenin/TCF pathway. <i>Leukemia</i> , 2007, 21, 535-540.	7.2	28
67	Induction Therapy for Newly Diagnosed Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e176-e186.	3.8	28
68	6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. <i>British Journal of Haematology</i> , 2021, 192, 843-852.	2.5	28
69	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. <i>Haematologica</i> , 2015, 100, 1294-1300.	3.5	27
70	Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. <i>Leukemia</i> , 2007, 21, 797-804.	7.2	26
71	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 6602-6615.	7.0	25
72	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. <i>Journal of Hematology and Oncology</i> , 2017, 10, 127.	17.0	25

#	ARTICLE	IF	CITATIONS
73	CD34 ⁺ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2005, 46, 177-183.	1.3	24
74	Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma. <i>Seminars in Oncology</i> , 2013, 40, 618-633.	2.2	24
75	Lenalidomide in combination with R ² ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from <sc>GELTAMO</sc> group. <i>British Journal of Haematology</i> , 2016, 173, 245-252.	2.5	24
76	Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. <i>Cells</i> , 2019, 8, 1432.	4.1	24
77	Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138 ⁺⁺ and CD138 ^{low} Subpopulations in Multiple Myeloma Cell Lines. <i>PLoS ONE</i> , 2014, 9, e92378.	2.5	23
78	Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant. <i>Blood</i> , 2018, 132, 595-595.	1.4	22
79	Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. <i>Haematologica</i> , 2015, 100, 1207-1213.	3.5	20
80	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.	7.2	20
81	Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMiDs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1075-1087.	4.1	19
82	Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. <i>Leukemia</i> , 2016, 30, 2026-2031.	7.2	19
83	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. <i>Haematologica</i> , 2017, 102, 2113-2124.	3.5	19
84	In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. <i>British Journal of Haematology</i> , 2006, 134, 37-44.	2.5	18
85	Filanesib for the treatment of multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 5-14.	4.1	18
86	Differential Diagnosis of IgM MGUS and WM According to B-Lymphoid Infiltration by Morphology and Flow Cytometry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 93-95.	0.4	16
87	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 85, 106197.	0.8	16
88	Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 821-822.	2.4	15
89	The DAC system and associations with multiple myeloma. <i>Investigational New Drugs</i> , 2010, 28, 28-35.	2.6	15
90	Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression. <i>Cancers</i> , 2021, 13, 2542.	3.7	15

#	ARTICLE	IF	CITATIONS
91	ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety. <i>Blood</i> , 2020, 136, 9-10.	1.4	15
92	Novel treatment regimens for Waldenström's macroglobulinemia. <i>Expert Review of Hematology</i> , 2010, 3, 339-350.	2.2	14
93	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	6.2	14
94	Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.. <i>Blood</i> , 2007, 110, 1178-1178.	1.4	14
95	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. <i>Haematologica</i> , 2011, 96, 687-695.	3.5	13
96	Multiple myeloma: treatment evolution. <i>Hematology</i> , 2012, 17, s3-s6.	1.5	13
97	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018, 103, e544-e548.	3.5	13
98	ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). <i>Blood</i> , 2019, 134, 3124-3124.	1.4	12
99	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. <i>Investigational New Drugs</i> , 2013, 31, 200-205.	2.6	11
100	Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. <i>Leukemia and Lymphoma</i> , 2019, 60, 462-470.	1.3	11
101	Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. <i>Blood Cancer Journal</i> , 2019, 9, 36.	6.2	11
102	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. <i>Blood</i> , 2021, 138, 1583-1589.	1.4	11
103	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.4	11
104	Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, e289-e291.	3.5	10
105	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. <i>Leukemia</i> , 2021, 35, 245-249.	7.2	10
106	Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. <i>Haematologica</i> , 2017, 102, 168-175.	3.5	9
107	Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2743.	3.7	9
108	Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016, 172, 625-628.	2.5	8

#	ARTICLE	IF	CITATIONS
109	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. <i>Leukemia</i> , 2018, 32, 2427-2434.	7.2	8
110	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1â€ acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. <i>British Journal of Haematology</i> , 2021, 192, 522-530.	2.5	8
111	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	6.2	8
112	Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 257-269.	1.8	7
113	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 504-516.	4.1	7
114	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. <i>Cancers</i> , 2020, 12, 3615.	3.7	7
115	Drugâ€ induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma. <i>HemaSphere</i> , 2019, 3, e192.	2.7	6
116	Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 178-178.	1.4	6
117	Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stemâ€ cell transplantation is a prognostic marker of longer progressionâ€ free survival and overall survival. <i>British Journal of Haematology</i> , 2022, 198, 278-287.	2.5	6
118	Cell Cycle Analysis of WaldenstrÃ¶m's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 250-252.	2.1	5
119	Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 567-569.	2.4	5
120	Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8529-8529.	1.6	5
121	ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)â€ Optimal dose, updated efficacy and safety results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8037-8037.	1.6	4
122	WaldenstrÃ¶mâ€™s Macroglobulinemia Immunophenotype. , 2017, , 21-34.		3
123	Melflufen for the treatment of multiple myeloma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 371-382.	3.1	3
124	Aggressive primary cutaneous <sc>CD</sc>30+ lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin. <i>International Journal of Dermatology</i> , 2018, 57, e153-e155.	1.0	2
125	Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. <i>Cells</i> , 2021, 10, 559.	4.1	2
126	LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8051-TPS8051.	1.6	2

#	ARTICLE	IF	CITATIONS
127	The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity.. Blood, 2007, 110, 1515-1515.	1.4	2
128	Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e241-e249.	0.4	2
129	Gene Expression Profiling of B-Lymphocyte and Plasma Cell Populations from Waldenstroïmâ€™s Macroglobulinemia. Comparison with Expression Patterns of the Same Cell-Counterparts from Other B-Cell Neoplasms.. Blood, 2005, 106, 503-503.	1.4	2
130	Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. Clinical Case Reports (discontinued), 2016, 4, 1096-1100.	0.5	1
131	Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?. Blood, 2019, 134, 5655-5655.	1.4	0